Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

Inclusion Criteria:

* Man or woman > 18 years old

* Patient with wAMD previously treated with ranibizumab (for less than 12 months before initiation of Aflibercept)

* Refractory to ranibizumab (defined by persistent fluid despite a treatment conducted according to the HAS French recommendations with at least 3 loading doses injections)

* Patient who switched to aflibercept (Eylea) between 1st of January 2014 and 30th June 2015

* Written informed consent given

Exclusion Criteria:

* Patient who do not meet the local indication criteria for aflibercept treatment. Contraindications listed in the local SmPC (Summary of Product Characteristics) have to be considered

* Recurrent patients with wAMD previously treated with ranibizumab and switched to aflibercept because of a high recurrence rate (recurrent patients described by Yonegawa et al.in AJO (American Journal of Ophthalmology )2013= exudation suppressed but high rate of injections)

* Patient who have been previously treated by any macular laser Visudyne/PD (Photodynamic therapy)

* Patient with a Visual Acuity (VA) <1/10

* Patient with Fibrosis involving Macula

* Patient with atrophic AMD

* Patient with any other retinal disease as myopia, diabetic retinopathy, diabetic macular oedema,chorioretinal anastomosis (CRA),, angioid streaks

* Patients taking part in an interventional study at the time of enrolment